Correlation of Soluble Suppression of Tumorigenicity 2 (ST2) With Golimumab (MK-8259) Response in Participants With Ulcerative Colitis (UC) (MK-8529-022).
Clinical trial NCT02318667 · COMPLETED
Trial details
- NCT number
- NCT02318667
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2015-02-27
- Primary completion
- 2017-06-21
- Enrollment
- 38
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.